Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent…
Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with…
Read More...
Read More...